Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial (British Journal of Cancer, (2024), 130, 1, (43-52), 10.1038/s41416-023-02474-w)

Correction to: British Journal of Cancer, published online 30 October 2023 In this article the unit of eotaxin blood concentration should be pg/mL, but there were two typos in ng/mL. This has been corrected. In section “Methods”, Study design and treatment, 3rd paragraph: Patients with high serum eotaxin levels (>81.02 ng/mL) were randomly assigned in a 2:1 ratio to receive either GemCap with GV1001 (GV1001 group) or GemCap (control group). It should read: Patients with high serum eotaxin levels (>81.02 pg/mL) were randomly assigned in a 2:1 ratio to receive either GemCap with GV1001 (GV1001 group) or GemCap (control group). Caption of figure 1: Flow diagram of patient disposition. A total of 511 pancreatic adenocarcinoma patients were screened, of 148 patients were enrolled. Patients with high serum eotaxin levels (>81.02 ng/mL) were randomly assigned in a 2:1 ratio to receive either Gemcitabine/Capecitabine with GV1001 (GV1001 group) or Gemcitabine/Capecitabine (control group). Finally, 148 patients were assigned to the GV1001 group (n = 75; all eotaxin-high) and control group (n = 73; 36 eotaxin-high and 37 eotaxin-low). It should read: Flow diagram of patient disposition. A total of 511 pancreatic adenocarcinoma patients were screened, of 148 patients were enrolled. Patients with high serum eotaxin levels (>81.02 pg/mL) were randomly assigned in a 2:1 ratio to receive either Gemcitabine/Capecitabine with GV1001 (GV1001 group) or Gemcitabine/Capecitabine (control group). Finally, patients were assigned to the GV1001 group (n = 75; all eotaxin-high) and control group (n = 73; 36 eotaxin-high and 37 eotaxin-low). The original article has been corrected.